New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
13:26 EDTAGN, SPPISpectrum regaining rights to bladder cancer drug not a positive, The Street says
Allergan (AGN) returning the rights to bladder cancer drug apaziquone back to Spectrum Pharmaceuticals (SPPI) is not a positive for Spectrum, contends The Street's Adam Feuerstein. Feuerstein says that Spectrum will need to conduct an additional phase III study of the drug and that the company is going to file for FDA approval based on two, separate studies that each failed to hit their primary endpoints with statistical significance. The Fly notes that Spectrum shares are up about 6.9% to $12.75 in early afternoon trading. Reference Link
News For SPPI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
09:17 EDTSPPICourt lifts injunction on sales of generic copy of Spectrum's Fusilev
The U.S. Court of Appeals for the Federal Circuit yesterday issued an order that lifted a temporary injunction put in place March 6 that had blocked Novartis' (NVS) Sandoz unit from selling a generic version of Spectrum Pharmaceuticals' (SPPI) colorectal cancer treatment Fusilev. The appeals court ruled that Spectrum failed to meet the requirements for an injunction pending appeal.
09:00 EDTSPPISpectrum revenue under 'major threat' after ruling, says Roth Capital
Roth Capital says an appeals court ruling yesterday denying Spectrum's injunction motion aimed to block Sandoz's generic Fusilev launch represents a "major threat" to Spectrum's revenue stream. Roth expects erosion of the company's Fusilev sales once the generic is launched and maintained a Neutral rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use